Market Research Logo

Interleukin 13 (IL13) - Pipeline Review, H2 2016

Interleukin 13 (IL13) - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Interleukin 13 (IL13) - Pipeline Review, H2 2016’, provides in depth analysis on Interleukin 13 (IL13) targeted pipeline therapeutics.

The report provides comprehensive information on the Interleukin 13 (IL13) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interleukin 13 (IL13) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Interleukin 13 (IL13)
  • The report reviews Interleukin 13 (IL13) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Interleukin 13 (IL13) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Interleukin 13 (IL13) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Interleukin 13 (IL13) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Interleukin 13 (IL13)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Interleukin 13 (IL13) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Introduction
Global Markets Direct Report Coverage
Interleukin 13 (IL13) Overview
Therapeutics Development
Interleukin 13 (IL13) - Products under Development by Stage of Development
Interleukin 13 (IL13) - Products under Development by Therapy Area
Interleukin 13 (IL13) - Products under Development by Indication
Interleukin 13 (IL13) - Pipeline Products Glance
Late Stage Products
Early Stage Products
Interleukin 13 (IL13) - Products under Development by Companies
Interleukin 13 (IL13) - Products under Development by Universities/Institutes
Interleukin 13 (IL13) - Therapeutics Assessment
Assessment by Monotherapy/Combination Products
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Interleukin 13 (IL13) - Companies Involved in Therapeutics Development
Celgene Corporation
Cell Medica Limited
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline Plc
MedImmune, LLC
Molecular Partners AG
Neovacs SA
Novartis AG
Sanofi
Interleukin 13 (IL13) - Drug Profiles
(dectrekumab + VAK-694) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dectrekumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lebrikizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit IL-4 and IL-13 for Atopic Dermatitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit IL-5 and IL-13 for Asthma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Inhibit IL-13 and IL-17 for Respiratory Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RPC-4046 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SAR-156597 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit IL-13 for Ulcerative Colitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tralokinumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target Interleukin 4 and Interleukin 13 for Allergies - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Interleukin 13 (IL13) - Dormant Projects
Interleukin 13 (IL13) - Discontinued Products
Interleukin 13 (IL13) - Featured News & Press Releases
Oct 13, 2016: Celgene to Present New Data on RPC4046 at UEGW and ACG Congresses
Feb 29, 2016: Roche provides update on two identical phase III studies of lebrikizumab in people with severe asthma
Oct 03, 2014: Receptos Announces First Patient Treated With Anti-Interleukin-13 Antibody in Phase 2 Trial for Eosinophilic Esophagitis
Aug 14, 2014: AstraZeneca advances tralokinumab to Phase III in severe asthma
May 12, 2014: AstraZeneca to present respiratory data on tralokinumab at ATS 2014 International Conference
Mar 05, 2014: Roche's lebrikizumab phase IIb data show reduction of asthma attack rates and improvement of lung function in adult patients with severe uncontrolled asthma
Aug 04, 2011: Roche’s Investigational Treatment For Asthma Meets Primary Endpoint In Phase II Study
Apr 15, 2008: MedImmune Advances Asthma Program With Start Of A Phase 2 Trial In Europe And Australia And First U.S.-Based Clinical Trial For Antibody Targeting IL-13
Mar 18, 2008: MedImmune Advances Clinical Development Of Antibody Targeting Interleukin-9 In Patients With Asthma
May 25, 2005: Preclinical Data Support Link Between IL-9 And Airway Hyper-responsiveness Associated With Asthma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for, H2 2016
Number of Products under Development by Therapy Area, H2 2016
Number of Products under Development by Indication, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Number of Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Assessment by Monotherapy/Combination Products, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Pipeline by Celgene Corporation, H2 2016
Pipeline by Cell Medica Limited, H2 2016
Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
Pipeline by GlaxoSmithKline Plc, H2 2016
Pipeline by MedImmune, LLC, H2 2016
Pipeline by Molecular Partners AG, H2 2016
Pipeline by Neovacs SA, H2 2016
Pipeline by Novartis AG, H2 2016
Pipeline by Sanofi, H2 2016
Dormant Projects, H2 2016
Dormant Projects (Contd..1), H2 2016
Discontinued Products, H2 2016
List of Figures
Number of Products under Development for, H2 2016
Number of Products under Development by Therapy Area, H2 2016
Number of Products under Development by Top 10 Indication, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy/Combination Products, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Type, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report